<DOC>
	<DOC>NCT00815906</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and tolerability of single doses of SBI-087 in Japanese subjects with rheumatoid arthritis.</brief_summary>
	<brief_title>Study Evaluating Single Doses Of SBI-087 In Japanese Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Must meet American College of Rheumatology criteria for rheumatoid arthritis with functional class I to III. Rheumatoid arthritis disease onset at &gt;16 years of age and duration of disease at least 6 months. Men or women of nonchildbearing potential (WONCBP), aged 20 to 70 years, inclusive at the screening visit. Any significant health problems other than rheumatoid arthritis. Treatment of greater than 10 mg of prednisone per day. Therapy with immunosuppressants within 6 months before study day 1</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>